Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Nicoletta Brega"'
Autor:
Yujun Xu, Xiaoliang Shi, Weifeng Wang, Lin Zhang, Shinghu Cheung, Marion Rudolph, Nicoletta Brega, Xiaowei Dong, Lili Qian, Liwei Wang, Shaohua Yuan, Daniel Shao Weng Tan, Kai Wang
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-12 (2023)
Abstract Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were found in a broad range of solid tumors as driver gene variants. However, the prevalence of NTRK fusions in Chinese solid tumor patients is rarely reported. Ba
Externí odkaz:
https://doaj.org/article/bb6c8783139748d5bda35ad87bf631e9
Autor:
Yuichi Ando, Sachi Morita, Tomoya Shimokata, Toyonori Tsuzuki, Shigeru Inafuku, Kenichiro Iwami, Nicoletta Brega, Takashi Akagawa, Toshiaki Tsujino, Tetsuya Ogawa
Publikováno v:
International Cancer Conference Journal. 11:242-246
For decades, no clear consensus existed on the standard treatment option for malignant tumors of the external auditory canal, an extremely rare disease. Here we report the case of a 55-year-old female patient with secretory carcinoma that originated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ee01e98dd4eb66202f36031fca6e191
https://doi.org/10.1007/s13691-022-00559-6
https://doi.org/10.1007/s13691-022-00559-6
Autor:
Giuseppe Giaccone, Nicoletta Brega, Michael Shnaidman, Brett E. Houk, William D. Figg, Baskar Mannargudi, Lokesh Jain, Wadih M. Zein, Sonja Crandon, Martin Gutierrez, Shivaani Kummar, Sylvia V. Alarcon, Yeong Sang Kim, Jane B. Trepel, Ronan J. Kelly, Arun Rajan
PDF file - 191KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3cfd090002f0e51aba43b6fba257d0
https://doi.org/10.1158/1078-0432.22443483.v1
https://doi.org/10.1158/1078-0432.22443483.v1
Autor:
Giuseppe Giaccone, Nicoletta Brega, Michael Shnaidman, Brett E. Houk, William D. Figg, Baskar Mannargudi, Lokesh Jain, Wadih M. Zein, Sonja Crandon, Martin Gutierrez, Shivaani Kummar, Sylvia V. Alarcon, Yeong Sang Kim, Jane B. Trepel, Ronan J. Kelly, Arun Rajan
Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.Methods: This was a single-institution,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9137d38582dab3191c2b0638950622b6
https://doi.org/10.1158/1078-0432.c.6519831.v1
https://doi.org/10.1158/1078-0432.c.6519831.v1
Autor:
Carsten Bokemeyer, Noman Paracha, Ulrik Lassen, Antoine Italiano, Sean D. Sullivan, Marisca Marian, Nicoletta Brega, Jesus Garcia-Foncillas
Publikováno v:
JCO Precision Oncology.
PURPOSE Larotrectinib, a highly specific tropomyosin receptor kinase (TRK) inhibitor, previously demonstrated high response rates in single-arm trials of patients with TRK fusion-positive cancer, but there are limited data on comparative effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fe5bb774ac0f9471b532fe88df20ef5
https://doi.org/10.1200/po.22.00436
https://doi.org/10.1200/po.22.00436
Autor:
Erin R. Rudzinski, Marc Ladanyi, Lauren L. Ritterhouse, Felix Sahm, Ricarda Norenberg, Hong Zheng, Chi Chen, Vadim Bernard-Gauthier, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Sinchita Roy-Chowdhuri
Publikováno v:
Cancer Research. 83:CT228-CT228
Background: NTRK gene fusions are oncogenic drivers in various tumor types. Laro, a highly selective and central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, is approved for the treatment of patients (pts) with TRK fusion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5c3a1927c36dfdf70eef05368cb7680
https://doi.org/10.1158/1538-7445.am2023-ct228
https://doi.org/10.1158/1538-7445.am2023-ct228
Autor:
Xiuning Le, Christina Baik, Jessica Bauman, Jill Gilbert, Marcia S Brose, Juneko E Grilley-Olson, Tejas Patil, Ray McDermott, Luis E Raez, Jennifer M Johnson, Lin Shen, Makoto Tahara, Alan L Ho, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Alexander Drilon, David S Hong
Publikováno v:
The Oncologist.
Background Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. We report the efficacy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e436076e4282f6d30c917fed3af147
https://doi.org/10.1093/oncolo/oyac080
https://doi.org/10.1093/oncolo/oyac080
Autor:
Alexander Drilon, Daniel S. W. Tan, Ulrik N. Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Victor Moreno, Shivaani Kummar, Jessica J. Lin
Publikováno v:
Drilon, A, Tan, D S W, Lassen, U N, Leyvraz, S, Liu, Y, Patel, J D, Rosen, L, Solomon, B, Norenberg, R, Dima, L, Brega, N, Shen, L, Moreno, V, Kummar, S & Lin, J J 2022, ' Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers ', JCO Precision Oncology, vol. 6, e2100418 . https://doi.org/10.1200/PO.21.00418
PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1b3ac2b9e98e4444d601a84aaed822
https://doi.org/10.1200/po.21.00418
https://doi.org/10.1200/po.21.00418
Autor:
Steven G Waguespack, Alexander Drilon, Jessica J Lin, Marcia S Brose, Ray McDermott, Mohammed Almubarak, Jessica Bauman, Michela Casanova, Anuradha Krishnamurthy, Shivaani Kummar, Serge Leyvraz, Do-Youn Oh, Keunchil Park, Davendra Sohal, Eric Sherman, Ricarda Norenberg, Josh D Silvertown, Nicoletta Brega, David S Hong, Maria E Cabanillas
Publikováno v:
European journal of endocrinology. 186(6)
Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b38c31972f1ff3e4cc313202f7fdc1a
https://pubmed.ncbi.nlm.nih.gov/35333737
https://pubmed.ncbi.nlm.nih.gov/35333737
Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib
Autor:
Marc Ladanyi, Sinchita Roy-Chowdhuri, Lauren Ritterhouse, Felix Sahm, Ricarda Norenberg, Kui Shen, Chi Chen, Marc Fellous, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Erin R. Rudzinski
Publikováno v:
Cancer Research. 82:CT545-CT545
Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Gene fusions arise from inter- and intrachromosomal rearrangements involving the 3’ region of the NTRK gene and the 5’ end of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1e01bbbcf71063e6cc6d15c2efd3b73
https://doi.org/10.1158/1538-7445.am2022-ct545
https://doi.org/10.1158/1538-7445.am2022-ct545